REGENXBIO Publishes Preclinical Data Highlighting RGX-202's Potential for Duchenne Muscular Dystrophy
REGENXBIO Inc. (NASDAQ:RGNX) is one of the biotech stocks to buy according to Wall Street analysts.
Regenxbio Inc. (RGNX)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Redmile Group Jeremy Green | 4,775,717 | $39,208,637 | -1% | 4.17% |
| 2. | AQR Capital Management Cliff Asness | 930,196 | $7,636,909 | +50% | 0.01% |
| 3. | Balyasny Asset Management Dmitry Balyasny | 797,100 | $6,544,191 | -44% | 0.01% |
| 4. | Renaissance Technologies Jim Simons | 735,200 | $6,035,992 | +148% | 0.01% |
| 5. | Integral Health Asset Management Bhagwan Jay Rao | 700,000 | $5,747,000 | -25% | 0.53% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $22.00 | 49,000 | $1,078,000.00 | 49,000 | 2015-09-22 | Filing | |
| $22.00 | 38,500 | $847,000.00 | 38,500 | 2015-09-22 | Filing | |
| $22.00 | 87,500 | $1,925,000.00 | 1,256,542 | 2015-09-22 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $7.91 | 20,602 | $163,046.29 | 475,103 | 2025-05-12 | Filing | |
| $10.11 | 10,000 | $101,052.00 | 11,286 | 2024-10-01 | Filing | |
| $12.34 | 700 | $8,638.00 | 11,286 | 2024-09-03 | Filing | |
| $11.50 | 9,300 | $106,950.00 | 11,986 | 2024-09-03 | Filing | |
| $15.00 | 100 | $1,500.00 | 11,286 | 2024-08-01 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 6,759,093 | $55,492,154 | 0% | |
| 2. | 3,852,025 | $31,625,125 | 0% | |
| 3. | 3,421,192 | $28,087,986 | 0% | |
| 4. | 1,843,645 | $15,136,325 | 0% | |
| 5. | 1,784,506 | $14,650,795 | 0% |
News See All
10 Biotech Stocks to Buy According to Wall Street Analysts
On July 8, Jared Holz, Mizuho, joined 'Closing Bell Overtime' on CNBC to discuss if the biotech sector is ready for a breakout.
REGENXBIO Inc. (RGNX): A Bull Case Theory
This stock is one of several featured in our latest research.
10 Promising SmallCap Stocks Under $1 Billion Market Cap
SmallCap stocks can often be overlooked by institutional investors, yet they offer outsized return potential for those willing to dig deeper.
REGENXBIO Inc. (NASDAQ:RGNX) Q1 2025 Earnings Call Transcript
Operator: Welcome, everyone to the First Quarter 2025 REGENXBIO Earnings Conference Call. At this time, all participants are in a listen-only mode.
REGENXBIO Inc. (NASDAQ:RGNX) Q4 2024 Earnings Call Transcript
Operator: Welcome everyone to the Fourth Quarter and Year End 2024 REGENXBIO Earnings Conference Call. At this time, all participants are in a listen-only mode.
10 Stocks on Jim Cramer’s Radar
Jim Cramer, the host of Mad Money, addressed some of Wall Street's primary concerns on Tuesday, offering insights into how the White House may interpret the ongoing issues surrounding President Donald...
REGENXBIO Inc. (NASDAQ:RGNX) Q3 2024 Earnings Call Transcript
Operator: Welcome everyone to the Q3 2024 REGENXBIO Earnings Conference Call. [Operator Instructions] Please be advised that today’s conference is being recorded.
REGENXBIO Inc. (NASDAQ:RGNX) Q2 2024 Earnings Call Transcript
Operator: Welcome everyone to the Q2 2024 REGENXBIO's Earnings Conference Call. All lines have been placed on mute to prevent background noise.
Top 10 Small-Cap Stocks with Highest Upside Potential
Most giant companies start as small-cap, but by continuously developing and growing their earnings, their share price increases making them large or mega-cap companies, and along the way smart investors...